Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
Amato, David A. Bruckner, Howard Guerry, DuPont IV Ash, Arlene S. Falkson, Geoffrey Borden, Ernest C. Creech, Richard H. Savlov, Edwin D. Cunningham, Thomas J.
Amato, David A.
Bruckner, Howard
Guerry, DuPont IV
Ash, Arlene S.
Falkson, Geoffrey
Borden, Ernest C.
Creech, Richard H.
Savlov, Edwin D.
Cunningham, Thomas J.
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Journal Article
Publication Date
1987-01-01
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Source
Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1007/BF00175301
Permanent Link to this Item
PubMed ID
3667165